Susquehanna International Group, LLP Solid Biosciences Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$0.51 - $7.56 $19,839 - $294,084	38,900 New	38,900 $18,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.79 $70,226 - $169,871	-94,900 Reduced 86.04%	15,400 $18,000
Q2 2021 Aug 11, 2021	BUY	$3.49 - $5.51 $91,089 - $143,811	26,100 Added 31.0%	110,300 $404,000
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $142,842 - $285,152	26,600 Added 46.18%	84,200 $466,000
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $107,800 - $272,650	35,000 Added 154.87%	57,600 $437,000
Q4 2019 Feb 14, 2020	SELL	$2.82 - $12.9 $67,962 - $310,890	-24,100 Reduced 51.61%	22,600 $101,000
Q3 2019 Nov 14, 2019	SELL	$4.33 - $11.64 $639,974 - $1.72 Million	-147,800 Reduced 75.99%	46,700 $483,000
Q2 2019 Aug 14, 2019	SELL	$4.6 - $10.13 $89,240 - $196,522	-19,400 Reduced 9.07%	194,500 $1.12 Million
Q1 2019 May 15, 2019	BUY	$7.19 - $32.37 $644,224 - $2.9 Million	89,600 Added 72.08%	213,900 $1.97 Million
Q4 2018 Feb 14, 2019	BUY	$21.32 - $46.34 $2.65 Million - $5.76 Million	124,300 New	124,300 $3.33 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.